

CELLTECH GROUP PLC  
Form 6-K  
November 19, 2003

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a - 16 or 15d - 16 of**

**the Securities Exchange Act of 1934**

For the month of **November, 2003**

Commission File Number: **1-10817**

**CELLTECH GROUP PLC**

(Translation of registrant's name into English)

**208 Bath Road, Slough, Berkshire SL1 3WE ENGLAND**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_).

Enclosure: Completion of OGS Integration dated 19 November 2003

**19th November 2003**

**CELLTECH GROUP PLC**

**CELLTECH ANNOUNCES COMPLETION OF OGS INTEGRATION PROCESS**

Celltech Group plc (LSE: CCH; NYSE: CLL) announced today that it has completed its integration of Oxford GlycoSciences (OGS), which was acquired in May 2003. This acquisition has provided Celltech with substantial assets, including six novel oncology research programmes supported by around 40 high quality scientists, a royalty stream from the marketed product Zavesca(R), and a Phase I development programme, CDP 923, for the treatment of certain inherited storage disorders. The acquisition has met Celltech's goal of being both cash and earnings neutral.

As part of its integration activities, Celltech has undertaken an extensive marketing process for the proteomics contract service business. Whilst there were many expressions of interest in this business, no formal offers were received. Consequently, Celltech has recently initiated the closure of this business. The cost of closure will be fully funded from the remaining cash reserves of OGS' wholly owned subsidiary Confirmant Limited, and will be reflected as an adjustment to the fair value of assets acquired in the second half financial results with no impact on Celltech's earnings.

**Contacts:**

|                |                                      |                      |
|----------------|--------------------------------------|----------------------|
| Peter Allen    | Deputy CEO and CFO                   | (44) (0) 1753 534655 |
| Richard Bungay | Director of Corporate Communications |                      |

|               |           |                       |
|---------------|-----------|-----------------------|
| Jon Coles     | Brunswick | (44) (0) 207 404 5959 |
| Wendel Carson | Brunswick |                       |

Celltech Group plc (LSE: CCH; NYSE: CLL) is one of Europe's largest biotechnology companies, with an innovative development pipeline, funded by its profitable, cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering. More details can be found at [www.celltechgroup.com](http://www.celltechgroup.com).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PLC

CELLTECH GROUP

(Registrant)

ALLEN

By: /s/ PETER

Officer

Peter Allen  
Chief Financial

Dated: 19 November, 2003